Featured Research

from universities, journals, and other organizations

Psoriasis drugs put to the test

Date:
January 18, 2010
Source:
University of Manchester
Summary:
Clinical trials to test the effectiveness of two prescription drugs for the debilitating skin condition psoriasis have revealed significant differences that should help inform physicians treating patients with the condition.

Clinical trials to test the effectiveness of two prescription drugs for the debilitating skin condition psoriasis have revealed significant differences that should help inform physicians treating patients with the condition.

Researchers at The University of Manchester compared the drugs etanercept and ustekinumab -- relatively new biological therapies that have proved effective in the management of moderate to severe psoriasis.

Little research has been done to test the benefit-risk profiles of these new biological agents or compare their relative effectiveness. The Manchester-led international study tested the two drugs on 903 patients with moderate to severe psoriasis over a 12-week period.

The team, headed by world-renowned dermatologist and psoriasis expert Professor Chris Griffiths, found that there was at least a 75% improvement in the severity of psoriasis symptoms in 56.8% of patients who received twice-weekly 50mg sub-cutaneous injections of etanercept after 12 weeks.

Ustekinumab was given to patients in two doses -- 45mg and 90mg -- and involved just two sub-cutaneous injections over the 12-week period. A 75% improvement in symptoms was observed in 67.5% of patients taking the 45mg dose and 73.8% receiving the 90mg dose.

"Our findings show that the efficacy of ustekinumab at either dosage was superior to that of high-dose etanercept using the 75% improvement measure over a 12-week period," said Professor Griffiths, who is based at Salford Royal Hospital, Greater Manchester.

"Similarly, a higher proportion of patients using ustekinumab were reported to have no or minimal disease symptoms after 12 weeks than those given etanercept -- 70.6% at 90mg ustekinumab compared to 49.0% receiving etanercept."

About one in 50 people are afflicted by psoriasis. The condition is currently incurable and causes significant impairment in the sufferer's quality of life. In severe cases more than 20% of the skin's surface area can be affected. Therapeutic agents used for the management of the condition commonly target the underlying inflammation.

Immunosupressive agents, such as methotrexate and cyclosporin, have proved effective in treating psoriasis but new biological agents that block selective stages of the body's inflammatory process now provide alternative therapies. Etanercept and ustekinumab are two such agents.

Etanercept, marketed as Enbrel by Amgen / Wyeth, works by blocking the actions of a chemical signal called TNF-∝ that is involved in the body's immune response. Ustekinumab, a drug marketed as Stelara by Centocor Research and Development, a subsidiary of Johnson & Johnson, targets two chemical signals involved in the immune system's response, called cytokines.

The research, published in the New England Journal of Medicine, also charted the number and type of adverse reactions for both drugs.

Professor Griffiths said: "The safety of ustekinumab and etanercept, including the rates and types of adverse events and laboratory abnormalities, appeared to be generally similar with short-term treatment.

"There were, however, more injection-site reactions with etanercept but this may be accounted for by the fact patients received more injections of this drug than ustekinumab."

He added: "The results of this study could have implications for determining the optimal approach to the treatment of psoriasis and, in particular, the need for therapeutic strategies targeting the body's immune system to provide the greatest benefit and safety."


Story Source:

The above story is based on materials provided by University of Manchester. Note: Materials may be edited for content and length.


Journal Reference:

  1. Griffiths et al. Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. New England Journal of Medicine, 2010; 362 (2): 118 DOI: 10.1056/NEJMoa0810652

Cite This Page:

University of Manchester. "Psoriasis drugs put to the test." ScienceDaily. ScienceDaily, 18 January 2010. <www.sciencedaily.com/releases/2010/01/100113172138.htm>.
University of Manchester. (2010, January 18). Psoriasis drugs put to the test. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2010/01/100113172138.htm
University of Manchester. "Psoriasis drugs put to the test." ScienceDaily. www.sciencedaily.com/releases/2010/01/100113172138.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
US to Track Everyone Coming from Ebola Nations

US to Track Everyone Coming from Ebola Nations

AP (Oct. 22, 2014) Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the US from Ebola-stricken nations will be monitored for symptoms for 21 days. (Oct. 22) Video provided by AP
Powered by NewsLook.com
Doctors Help Paralysed Man Walk Again, Patient in Disbelief

Doctors Help Paralysed Man Walk Again, Patient in Disbelief

AFP (Oct. 22, 2014) Polish doctors describe how they helped a paralysed man walk again, with the patient in disbelief at the return of sensation to his legs. Duration: 1:04 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins